The following constitutes a breach subject to a financial penalty:
1° Failure by manufacturers, importers or distributors of active substances to comply with the good manufacturing and distribution practices referred to in the first and second paragraphs of article L. 5138-3 ;
2° Failure by any pharmaceutical establishment mentioned in article L. 5124-1, dispensing pharmacies, pharmacies for internal use or doctors to ensure that the active substances they use comply with good manufacturing and distribution practice, and failure by pharmaceutical establishments to carry out audits or have audits carried out to ensure compliance at active substance manufacturing and distribution sites;
3° Failure by any pharmaceutical establishment referred to in Article L. 5124-1 to determine the good practices applicable to the manufacture of excipients by carrying out a formalised risk assessment and to ensure that they are complied with.